PharmaCept is an innovative company based in Berlin. Since 1999, we have been developing and marketing products for the locoregional treatment of tumor diseases worldwide. Our focus is on the treatment of primary and secondary liver and lung tumors as well as non-muscle invasive bladder cancer, NMIBC.

Better therapy results for a better quality of life for patients

Our products are renowned for their therapeutic efficacy and good tolerability. PharmaCept strives to continuously  improve the therapeutic results and the associated quality of life of its patients.

New products for innovative therapies

PharmaCept collaborates with clinics and research institutions to research innovative drugs and methods for the treatment of tumor diseases in order to offer patients the best possible therapy options.

Material: Amilomer (DSM* 35/50).

Half-life: 30-40 minutes.

Average size of microspheres: 50 µm ± 7 ųm.

Size distribution of microspheres: Min 95% 20-90 µm // Max 4.0% > 90 µm // Max 2.5% < 20 µm.

Indication: Transarterial chemoembolization (TACE) of inoperable liver and lung tumors.

Dosage: 2.5 – 7.5 ml (150 – 450 mg), depending on tumor size and vascularization, arterial blood flow and arteriovenous shunt volume. Maximum dose of 15 ml (900 mg) possible in individual cases.

Mechanism of action: Reduction of blood flow causes short term ischemia in addition to a local concentration increase of the simultaneously applied cytostatic agent.

Package size: 450 mg Amilomer in 7.5 ml saline solution.

Article number: 15879771.

Active ingredient: Cisplatin (Cytostatic).

Dosage form: Powder for the preparation of an injection solution.

Indication: Metastatic testicular tumors, metastatic ovarian tumors, advanced bladder carcinoma, squamous cell carcinoma of the head and neck, and lung carcinoma (small cell and non-small-cell).

Pack size: 50 mg cisplatin powder in a vial.

PZN: 14169257, prescription only.